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Abstract
Background: Osteoporotic fractures are associated with mortality in postmenopausal woman. Whether raloxifen
treatment after vertebroplasty can reduce mortality is unclear in this group. To compare the effect of raloxifene and
no osteoporosis treatment on the risk of mortality after vertebroplasty, we designed this study.
Methods: This was a retrospective study (January 2001 to December 2007). Follow-up for each participant was calculated
as the time from inclusion in the study to the time of death, or to December 31st, 2013, whichever occurred first. All of
the patients underwent baseline bone density studies, and age and body mass index (kg/m2) were recorded. All
associated medical diseases such as diabetes, hypertension, and liver and renal disease were recorded.
Results: One hundred and forty-nine patients with vertebral fractures were enrolled, of whom 51 used raloxifene
and 98 patients did not receive any anti-osteoporotic therapy. At the end of the follow-up period, 62 patients
had died and 87 were still alive. The treated patients had a lower mortality rate than those who did not receive
treatment (P = 0.001, HR = 3.845, 95 % CI 1.884-7.845). The most common cause of mortality was sepsis, and those
who received raloxifene had a lower rate of sepsis compared to those who did not receive treatment (P < 0.001).
Conclusions: Effective treatment with raloxifene may had a lower mortality rate in patients with postmenopausal
osteoporosis-related vertebral fractures after vertebroplasty.
Background
Raloxifene is a selective estrogen-receptor modulator that
has been shown to prevent bone loss. In postmenopausal
women with osteoporosis, treatment with raloxifene has
been shown to decrease markers of bone turnover by 30
to 40 % after one year of usage, and increase bone density
at several scanning sites by 2 to 3 % after three years of
use [1–3]. Raloxifene has also been shown to decrease the
incidence of vertebral fractures by 30 to 50 %, depending
on dosage, but not the incidence of hip fractures or other
non-vertebral fractures [1].
Osteoporotic fractures of the spine are common with
aging, and the lifetime risk of a symptomatic vertebral
compression fracture has been estimated to be 18 % for
women and 11 % for men [4]. In addition, painful, clinic-
ally apparent vertebral fractures have been reported to
increase overall mortality by up to 15 % [4, 5]. Further-
more, some individuals will become disabled by severe
pain that lasts for longer than 2 to 3 months.
Data from studies on raloxifene used to reduce the risk
of fractures can provide a way to test the hypothesis that
treating osteoporosis reduces the risk of death. If
treating osteoporosis does have a positive impact on
mortality, there would be several important potential
implications for managing skeletal health specifically,
and for health care for women in general. Therefore,
in this study, we investigated whether raloxifene treat-
ment affects mortality rates in postmenopausal woman
with vertebral fractures.
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Methods
This was a retrospective review of osteoporosis patients
with vertebral fractures. The Institutional Review Board
of Kaohsiung Chang Gang Memorial Hospital approved
this study, and it was conducted in accordance with the
Declaration of Helsinki and the International Conference
on Harmonization of Good Clinical Practice Guidelines.
According to Taiwan law, no additional informed con-
sent was required, and patient information was anon-
ymized and de-identified before data analysis.
The inclusion criteria were postmenopausal women
with a radiological diagnosis of a vertebral fracture
followed by a vertebral augmentation procedure for a
painful vertebral compression fracture, and failure of
conservative pain management. All patients were exam-
ined with magnetic resonance imaging, and we obtained
the electronic medical records of all patients who under-
went vertebral augmentation procedures. Patients were
excluded if their fracture had a pathological source or
had been caused by more than minimal trauma. We
choose those with raloxifen treatment (60 mg/d after
vertebroplasy) and those without treatment with any
anti-osteoporotic therapy for comparison.
Follow-up for each participant was calculated as the
time from inclusion in the study to the time of death, or
to December 31st, 2013, whichever occurred first. All of
the patients underwent baseline bone density studies,
and age and body mass index (kg/m2) were recorded. All
associated medical diseases such as diabetes, hyperten-
sion, and liver and renal disease were recorded.
Statistical analysis
Statistical analysis was performed using SPSS software,
version 21.0 (SPSS, Chicago, IL, USA). Kaplan-Meyer
analysis with the log rank test was performed for differ-
ent groups. Comparisons between independent means
were analyzed using the independent t test, and rela-
tionships between categorical variables were evaluated
by the chi-square test. Cox regression analysis was used
to adjust for potential confounding factors. A P value
of less than 0.05 was considered to be statistically
significant.
Results
One hundred and forty-nine patients with vertebral
fractures were enrolled in this study, of whom 51 used
raloxifene and 98 did not receive anti-osteoporotic
therapy. All were grade 3 by semiquantitative grading
scale for vertebral fracture and T score < -2.5 with bone
densitometry. The mean age at the index day was 74.24 ±
7.62 years in the raloxifene group and 72.52 ± 9.70 years
in those who did not receive treatment. The mean follow-
up period was 7.08 ± 3.67 years.
At the end of the follow-up period, 62 patients had
died and 87 were still alive. The patients who received
raloxifene survived for longer than those who did not
receive treatment (P = 0.04). There were no significant
differences in body mass index, number of vertebral
fractural, previous hip fracture,or underlying diseases
including diabetes, hypertension, cardiovascular dis-
ease, pulmonary disease, liver disease, or neurological
diseases (Table 1).
Raloxifene therapy had a significant effect on survival
according to Kaplan-Meier curves (Fig. 1). After adjust-
ing for potential confounding factors such as diabetes,
hypertension, cardiovascular disease, pulmonary disease,
liver disease and neurological diseases, the patients treated
with raloxifene still had a lower mortality rate than those
who did not receive treatment (P = 0.001, HR = 3.845,
95 % CI 1.884-7.845) (Table 2). The most common cause
of mortality overall was sepsis, however the rate of
sepsis was significantly lower in the raloxifene group
compared to the no treatment group (P < 0.001) (Fig. 2).
Discussion
Raloxifene is a non-steroidal benzothiophene analog
that has been shown to inhibit the growth of estrogen-
receptor-dependent dimethylbenzanthracene-induced
mammary tumors and reduce the occurrence of
nitrosomethylurea-induced mammary tumors in rats.
It is classified as a selective estrogen-receptor modula-
tor on the basis of studies in which it prevented bone
Table 1 Baseline characteristics of the study patients
Raloxifene No treatment P value
Age (years) 74.24 ± 7.62 72.52 ± 9.70 0.238
Body mass index (kg/m2) 22.80 ± 4.82 24.12 ± 4.85 0.116
Survival years 8.06 ± 2.63 6.11 ± 4.33 0.004
Fracture no (spine) 1.83 ± 1.07 1.48 ± 1.48 0.158
Previous hip fracture No 46(90.2 %) 88(89.8 %) 0.592
Yes 5(9.8 %) 10(10.2 %)
Diabetes No 38(74.5 %) 73(74.5 %) 0.581
Yes 13(25.5 %) 25(25.5 %)
Hypertension No 25(49.0 %) 46(46.9 %) 0.864
Yes 26(51.0 %) 52(53.1 %)
Neurological disease No 50(98.0 %) 97(99.0 %) 1
Yes 1(2.0 %) 1(1.0 %)
Pulmonary disease No 49(96.1 %) 92(93.9 %) 0.716
Yes 2(3.9 %) 6(6.1 %)
Cardiovascular disease No 49(96.1 %) 93(94.9 %) 1
Yes 2(3.9 %) 5(5.1 %)
Liver disease No 47(92.2 %) 91(92.9 %) 1
Yes 4(7.8 %) 7(7.1 %)
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loss and lowered serum cholesterol concentrations
without stimulating the endometrium [6–9].
Theoretically, effective prevention and treatment strat-
egies can be implemented once a high-risk individual
has been identified. It is essential that evidence-based
recommendations be incorporated into clinical practice
[10]. Despite the availability of effective treatment in the
Taiwan health care system, effective osteoporosis inter-
ventions are not optimal for women with a history of
osteoporotic vertebral fractures. This is consistent with
a population-based study, in which only one in five
patients with a fragility fracture received treatment for
osteoporosis within the following year [11]. Other stud-
ies have also reported insufficient levels of treatment,
with the probability of being treated being inversely
related to age and lower among older women [12–14].
Decisions regarding the treatment of postmeno-
pausal osteoporosis should be based on the patient’s
risk for fractures, drug efficacy and the side effects of
these drugs. Individuals with a fragility vertebral fracture
should always be treated when not contraindicated, be-
cause the risk of subsequent vertebral fractures is very
high [15]. Based on the scientific evidence, raloxifene ap-
pears to be a good option.
Established osteoporosis has been associated with a
high mortality rate after adjusting for age and comor-
bidities [16, 17], and prevalent vertebral deformities
have been reported to predict increased mortality and










Fig. 2 Comparison of the of the death between raloxifene and
placebo group
Table 2 Effect of raloxifene on mortality after adjusting for
variables
Regression coefficient SE P value HR
Age (years) .029 .018 .105 1.029
Body mass index (kg/m2) -.032 .030 .289 .968
Diabetes -.567 .294 .054 .567
Hypertension -.159 .273 .560 .853
Neurological disease .235 1.057 .824 1.265
Liver disease -.554 .497 .265 .574
Cardiovascular disease .676 .730 .355 1.966
Pulmonary disease .214 .604 .723 1.239
Raloxifene use 1.347 .364 .000 3.845
Abbreviations: SE: standard error; HR: hazard ratio
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fracture rates in both men and women [18–23]. Treat-
ment for osteoporosis with established methods for
vertebral and non-vertebral fractures has been reported
to reduce mortality in older, frailer individuals with
osteoporosis who are at a high risk of fractures [24–26].
In clinical practice, some patients with vertebral frac-
tures do not receive medical therapy after vertebroplasty,
and this may contribute to subsequent vertebral frac-
tures and increased mortality [27]. Our results show that
raloxifene therapy can reduce mortality, underscoring
the importance of educating patients with osteoporosis
about the value of raloxifene therapy. We also noted a
decreased incidence of sepsis after raloxifene treatment
compared to those who did not receive treatment.
It is not clear how raloxifene reduce risk of death
due to infection [28]. Estrogen receptor ligands have
been shown to reduce bacteremia and mortality in ex-
perimental models of infection [29]. Because vertebral
fractures have been associated with increased pulmon-
ary causes of mortality [30], so vertebral fracture
might be associated with shallow respiration and in-
creased risk of pneumonia and associated sepsis. So
raloxifen reduces the risk of sepsis by decrease verte-
bral fracture.
A possible reason for this may be because raloxifene
therapy decreases the frequency of subsequent frac-
tures, thereby improving mobility and decreasing the
infection rate.
There are several limitations to his study. First, the
number of vertebral fractures was probably underesti-
mated, given the inherent difficulty of diagnosing them.
For instance, only about a third of cases of all vertebral
deformities detected on radiographs receive medical
attention, and less than 10 % require admission to hos-
pital. Second, the sample size was small. Third, there
was a lack of complete bone mineral density data after
osteoporosis treatment. However, in this single-center
cohort, we collected as much data as possible, and this
study included only fragility fractures in patients older
than 50 years without a secondary etiology. Thus, the
patients’ fractures were due to osteoporosis.
This study also has a number of strengths. First, it
was a long-term cohort study with a mean follow-up
period of 7 years, which made it possible to gather suf-
ficient follow-up data on survival. In addition, baseline
magnetic resonance imaging scans were taken for each
participant, all of whom had clinically diagnosed verte-
bral fractures. Thus, we were able to exclude other
secondary causes of vertebral fractures such as cancer
or pyogenic infections.
Conclusions
In conclusion, our results showed that raloxifene ther-
apy can reduce the mortality rate of postmenopausal
women with osteoporotic vertebral fractures. After adjust-
ing for comorbidities, the patients who received raloxifene
therapy still had a lower mortality rate. Thus, optimal
management with raloxifene may reduce the risk of death.
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